Fresh analysis reveals that individuals who come off new weight-loss injections like Wegovy and Mounjaro can put back on lost weight much more quickly than those who halt conventional lifestyle programs.
Findings released in a major medical journal shows that while overweight individuals can lose about a fifth of their body weight while using the jabs, the mass comes back at an average rate of nearly a kilo each month after stopping.
"Users using these medications should be cognizant of the potential of quick weight regain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
This pace of regain implies a return to original mass in about a year and a half.
Analyzing Therapies
The study, which reviewed 37 of trials involving over 9,000 of patients, contrasted the results of the injectable medications with older methods.
Scientists point out that people who lose weight through dieting generally experience a slower creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Doctors suggest the way of the drugs accounts for the heightened regain.
GLP-1 drugs copy a natural hormone called GLP-1, which controls hunger.
"Long-term administration of GLP-1 concentrations several times higher than normal might result in the system to produce less of its own natural hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement means hunger is unsuppressed, making overeating a significant risk."
A Lifelong Issue?
The NHS suggest the jabs for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, given the likelihood of weight regain, the treatment is often life-long.
This view is echoed by pharmaceutical companies, who say that the results "underscore the long-term character of obesity," akin to managing conditions like high blood pressure.
User Testimonies
Individuals who have stopped the jabs explain a intense return of appetite.
"It was like a switch flipping and I was suddenly starving," described one woman.
This difficulty is exacerbated if patients have not developed sustainable lifestyle or habit modifications during therapy.
Significant Adoption
Figures show that millions of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Use is greater among women than males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, researchers stress that while GLP-1 drugs are potent tools for weight loss, they are not a permanent cure and lasting health benefits relies on integrated behavioural support.